GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » PB Ratio

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) PB Ratio : 3.82 (As of Sep. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-09-27), Chongqing Genrix Biopharmaceutical Co's share price is ¥26.03. Chongqing Genrix Biopharmaceutical Co's Book Value per Share for the quarter that ended in Jun. 2024 was ¥6.82. Hence, Chongqing Genrix Biopharmaceutical Co's PB Ratio of today is 3.82.

Good Sign:

Chongqing Genrix Biopharmaceutical Co Ltd stock PB Ratio (=3.3) is close to 1-year low of 3.3

The historical rank and industry rank for Chongqing Genrix Biopharmaceutical Co's PB Ratio or its related term are showing as below:

SHSE:688443' s PB Ratio Range Over the Past 10 Years
Min: 3.25   Med: 4.66   Max: 5.85
Current: 3.82

During the past 5 years, Chongqing Genrix Biopharmaceutical Co's highest PB Ratio was 5.85. The lowest was 3.25. And the median was 4.66.

SHSE:688443's PB Ratio is ranked worse than
67.55% of 1282 companies
in the Biotechnology industry
Industry Median: 2.405 vs SHSE:688443: 3.82

During the past 12 months, Chongqing Genrix Biopharmaceutical Co's average Book Value Per Share Growth Rate was -18.90% per year.

Back to Basics: PB Ratio


Chongqing Genrix Biopharmaceutical Co PB Ratio Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co PB Ratio Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - - - 5.26

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.68 3.82 5.26 5.55 4.36

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's PB Ratio

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's PB Ratio falls into.



Chongqing Genrix Biopharmaceutical Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Chongqing Genrix Biopharmaceutical Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2024)
=26.03/6.815
=3.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Chongqing Genrix Biopharmaceutical Co PB Ratio Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines